Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Declines By 59.4%

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 69,800 shares, a drop of 59.4% from the March 31st total of 171,800 shares. Based on an average daily trading volume, of 701,300 shares, the short-interest ratio is presently 0.1 days.

Astellas Pharma Trading Up 0.1 %

OTCMKTS:ALPMY opened at $9.55 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.31. The business’s 50 day moving average is $10.53 and its two-hundred day moving average is $11.45. Astellas Pharma has a 52 week low of $9.15 and a 52 week high of $16.91. The company has a market cap of $17.28 billion, a PE ratio of 27.26, a P/E/G ratio of 1.65 and a beta of 0.32.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Thursday, April 25th. The company reported $0.11 EPS for the quarter. Astellas Pharma had a return on equity of 5.85% and a net margin of 1.20%. The company had revenue of $2.79 billion for the quarter. On average, analysts predict that Astellas Pharma will post 0.44 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.